Jarne Elleholm's career has taken him from operating roles at companies like Lundbeck UK and Whatman International, through leading Aresa, a company known for genetically modified weed used in landmine detection, before moving into biosolutions venture investing and hands-on company building as co-founder and executive chairman of EvodiaBio and as chairman of Chromologics. He argues that biosolutions startups usually fail not because of the science but because of weak commercialization, and he has spoken publicly about the need for stronger local risk capital in Denmark and Europe to support this kind of science-based venture work.